{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:09:55Z","timestamp":1759496995700},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.eururo.2008.04.027","type":"journal-article","created":{"date-parts":[[2008,4,19]],"date-time":"2008-04-19T09:20:48Z","timestamp":1208596848000},"page":"184-192","source":"Crossref","is-referenced-by-count":17,"title":["Cizolirtine Citrate, an Effective Treatment for Symptomatic Patients with Urinary Incontinence Secondary to Overactive Bladder: A Pilot Dose-Finding Study"],"prefix":"10.1016","volume":"56","author":[{"given":"Roberto","family":"Mart\u00ednez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Abad\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pere","family":"Ara\u00f1\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Perales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Sust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Conejero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.04.027_bib1","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0140-6736(06)67925-7","article-title":"Urinary incontinence in women","volume":"367","author":"Norton","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2008.04.027_bib2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/nau.10052","article-title":"The standardisation of terminology of Lower Urinary Tract Function: report from the Standardisation Sub-committee of the International Continence Society","volume":"21","author":"Abrams","year":"2002","journal-title":"Neurouro Urrodyn"},{"key":"10.1016\/j.eururo.2008.04.027_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.eururo.2006.04.018","article-title":"The current and future burden and cost of overactive bladder in five European countries","volume":"50","author":"Reeves","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1124\/pr.56.4.4","article-title":"Pharmacology of the lower urinary tract: basis for current and future treatment of urinary incontinence","volume":"56","author":"Andersson","year":"2004","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.eururo.2008.04.027_bib6","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1524-4733.2005.00041.x","article-title":"Persistence and adherence of medications for chronic overactive bladder\/urinary incontinence in the California Medicaid Program","volume":"8","author":"Yu","year":"2005","journal-title":"Value Health"},{"key":"10.1016\/j.eururo.2008.04.027_bib7","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1368-5031.2005.00617.x","article-title":"Persistence with antimuscarinic therapy in patients with overactive bladder","volume":"59","author":"Haab","year":"2005","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2008.04.027_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.neuropharm.2006.08.017","article-title":"Evidence for adenosine- and serotonin-mediated antihyperalgesic effects of cizolirtine in rats suffering from diabetic neuropathy","volume":"52","author":"Aubel","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eururo.2008.04.027_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.pain.2004.03.001","article-title":"Antihyperalgesic effects of cizolirtine in diabetic rats: behavioral and biochemical studies","volume":"110","author":"Aubel","year":"2004","journal-title":"Pain"},{"key":"10.1016\/j.eururo.2008.04.027_bib10","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S0028-3908(00)00186-6","article-title":"The novel analgesic, cizolirtine, inhibits the spinal release of substance P and CGRP in rats","volume":"40","author":"Ballet","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.eururo.2008.04.027_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0014-2999(94)90436-7","article-title":"Antagonism of substance P and related peptides by RP 67580 and CP-96345, at tachykinin Nk1 receptor sites, in the rat urinary bladder","volume":"251","author":"Montier","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.eururo.2008.04.027_bib12","unstructured":"S\u00e1enz de Tejada I. Evaluation of the effects of the administration of cizolirtine and other seven molecules on urodynamic function in rats. Instituto de Medicina Sexual (Madrid) 2005; Esteve unpublished data."},{"key":"10.1016\/j.eururo.2008.04.027_bib13","unstructured":"Cizolirtine Investigator's Brochure, 18th edition. April 2007."},{"key":"10.1016\/j.eururo.2008.04.027_bib14","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1464-410X.2004.04606.x","article-title":"Randomized, double-blind placebo and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder","volume":"93","author":"Chapple","year":"2004","journal-title":"BJU International"},{"key":"10.1016\/j.eururo.2008.04.027_bib15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.eururo.2005.05.015","article-title":"A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial","volume":"48","author":"Chapple","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2006.10.005","article-title":"Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder","volume":"51","author":"Dmochowski","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1442-2042.2002.00460.x","article-title":"Tolterodine: as effective but better tolerated than oxybutynin in Asian Patients","volume":"9","author":"Lee","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib18","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1046\/j.1464-410X.2003.03076.x","article-title":"Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder","volume":"91","author":"Mattiasson","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2008.04.027_bib19","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1097\/01.ju.0000103540.71683.e5","article-title":"Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity","volume":"171","author":"Landis","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2004.01.008","article-title":"Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder","volume":"45","author":"Haab","year":"2004","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib21","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0022-5347(05)66095-8","article-title":"A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence","volume":"166","author":"Davila","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1532-5415.2000.tb04692.x","article-title":"Combined behavioral and drug therapy for urge incontinence in older women","volume":"48","author":"Burgio","year":"2000","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.eururo.2008.04.027_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2007.07.009","article-title":"Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder","volume":"52","author":"Chapple","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.4065\/78.6.687","article-title":"Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial","volume":"78","author":"Diokno","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2008.04.027_bib26","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0302-2838(02)00177-X","article-title":"Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder","volume":"41","author":"Kreder","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0022-5347(05)64684-8","volume":"168","author":"Dmochowsi","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.04.027_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0167-0115(01)00285-3","article-title":"Tachykinins as modulators of the micturition reflex in the central and peripheral nervous system","volume":"101","author":"Lecci","year":"2001","journal-title":"Regul Pept"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808004739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808004739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,29]],"date-time":"2018-12-29T13:26:21Z","timestamp":1546089981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808004739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0302283808004739"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.04.027","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}